促甲状腺激素释放激素（TRH）与慢性精神分裂症。一项对照研究。

Thyrotropin-releasing hormone (TRH) inchronic schizophrenia. A controlled study.

作者信息

Lindström L H, Gunne L M, Ost L G, Persson E

出版信息

Acta Psychiatr Scand. 1977 Jan;55(1):74-80. doi: 10.1111/j.1600-0447.1977.tb00142.x.

DOI:10.1111/j.1600-0447.1977.tb00142.x

Abstract

A controlled study on the effect of synthetic Thyrotropin-Releasing Hormone (TRH) versus placebo in 10 drug-free chronic schizophrenics is presented. TRH 600 mug or placebo was administered intravenously on 4 consecutive days in a double-blind cross-over design and the schizophrenic symptoms were scored daily by use of two rating scales (CPRS and NOSIE). Blood samples were taken before and 30 and 45 minutes after the first and the fourth injection and analyzed for TSH. No changes in symptom intensity were found during the TRH or placebo treatment period and no difference was obtained between the two treatments. The dose of TRH used caused a significant increase in the plasma level of TSH which indicated a normal pituitary responsiveness to TRH. The data do not support the notion that TRH has a beneficial effect in chronic schizophrenic patients.

摘要

本文呈现了一项针对10名未服用药物的慢性精神分裂症患者的对照研究，比较了合成促甲状腺激素释放激素（TRH）与安慰剂的效果。采用双盲交叉设计，连续4天静脉注射600微克TRH或安慰剂，每天使用两种评定量表（CPRS和NOSIE）对精神分裂症症状进行评分。在第一次和第四次注射前、注射后30分钟和45分钟采集血样，分析促甲状腺激素（TSH）。在TRH或安慰剂治疗期间，未发现症状强度有变化，两种治疗之间也未发现差异。所用TRH剂量导致血浆TSH水平显著升高，这表明垂体对TRH反应正常。这些数据不支持TRH对慢性精神分裂症患者有有益作用的观点。